Article Figures & Data
Tables
- TABLE 1.
Clinical and Therapeutic Details of 18 Patients with DTC or Hyperthyroidism and H. pylori Infection Treated with 131I
Patient no. Age (y) Sex Diagnosis Treatment dose (GBq) Hp stool Ag before 131I Hp stool Ag after 131I 1 58 M HT 0.74 Positive Positive 2 44 F PTC 0.15 Positive Positive 3 60 F PTC 0.2 Positive Positive 4 36 F PTC 0.2 Positive Positive 5 61 M PTC 5.5 Positive Positive 6 50 F PTC 5.5 Positive Positive 7 38 F PTC 5.5 Positive Positive 8 43 F PTC 3.7 Positive Positive 9 43 M HT 1.1 Positive Positive 10 43 F PTC 5.5 Positive Positive 11 31 F PTC 0.2 Positive Positive 12 33 F PTC 5.5 Positive Positive 13 50 F PTC 3.7 Positive Positive 14 41 F PTC 5.5 Positive Negative Hp = H. pylori; Ag = antigen; HT = hyperthyroidism; PTC = papillary thyroid carcinoma.
- TABLE 2.
Comparison of Present Findings with Previous Findings on 131I Effect on H. pylori Eradication
Hp-positive patients before 131I therapy (n) 131I therapy dose (GBq) Hp-negative patients after 131I therapy (n) Test used to evaluate Hp infection Reference 14 with HT or PTC 0.15–5.5 1 SAT Present study 71 with DTC 3.7–7.4 23 UBT (11) 42 with DTC NA 5 UBT (14) 18 with DTC 3.7–7.4 0 SAT (17) Hp = H. pylori; HT = hyperthyroidism; PTC = papillary thyroid carcinoma; SAT = stool antigen test; UBT = urea breath test; NA = not applicable.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.